Table 1.
SRA737-related treatment-emergent adverse events of any grade reported by ≥10% of overall patient group.
| Preferred term | SRA737 dose ≤ 800 mg (N = 58) n (%) | SRA737 dose > 800 mg (N = 49) n (%) | Overall (N = 107) n (%) |
|---|---|---|---|
| Any SRA737-related treatment-emergent adverse event (TEAE) | 51 (87.9) | 47 (95.9) | 98 (91.6) |
| Diarrhoea | 33 (56.9) | 34 (69.4) | 67 (62.6) |
| Nausea | 32 (55.2) | 32 (65.3) | 64 (59.8) |
| Vomiting | 21 (36.2) | 28 (57.1) | 49 (45.8) |
| Fatigue | 14 (24.1) | 27 (55.1) | 41 (38.3) |
| Decreased Appetite | 12 (20.7) | 7 (14.3) | 19 (17.8) |
| Neutropenia | 10 (17.2) | 7 (14.3) | 17 (15.9) |
| Anaemia | 5 (8.6) | 11 (22.4) | 16 (15.0) |